Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018009811) USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/009811 International Application No.: PCT/US2017/041119
Publication Date: 11.01.2018 International Filing Date: 07.07.2017
IPC:
G01N 33/574 (2006.01) ,C07K 16/30 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
GENENTECH, INC. [US/US]; 1 DNA Way South San Francisco, California 94080-4990, US (AE, AG, AM, AO, AU, AZ, BB, BF, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CI, CL, CM, CO, CR, CU, DJ, DM, DO, DZ, EC, EG, GA, GD, GE, GH, GM, GN, GQ, GT, GW, HN, ID, IL, IR, JO, JP, KE, KG, KH, KM, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LY, MA, MD, ME, MG, ML, MN, MR, MW, MX, MY, MZ, NA, NE, NG, NI, NZ, OM, PA, PE, PG, PH, QA, RU, RW, SA, SC, SD, SG, SL, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW)
F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124 4070 Basel, CH (AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
Inventors:
LACKNER, Mark; US
MASLYAR, Daniel; US
WANG, Yulei; US
DARBONNE, Walter; US
HUMKE, Eric; US
Agent:
RODRIGUEZ, Roberto, K.; US
ARJOMAND, Mehran; US
BANKO, Max; US
BASOL, Erol, C.; US
AMII, Lisa, A.; US
Priority Data:
62/360,02708.07.2016US
Title (EN) USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
(FR) UTILISATION DE LA PROTÉINE 4 D'ÉPIDIDYME HUMAINE (HE4) POUR ÉVALUER LA SENSIBILITÉ À UN TRAITEMENT D'UN CANCER POSITIF POUR MUC16
Abstract:
(EN) The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
(FR) La présente invention concerne des procédés et des kits ou des articles manufacturés associés à ceux-ci qui peuvent trouver une utilisation, entre autres, dans l'évaluation de la sensibilité de cancers à des antagonistes de MUC16 par suivi de l'expression de HE4. Dans certains modes de réalisation, les procédés comprennent la mesure du niveau d'expression de HE4 dans un échantillon prélevé sur un sujet, la comparaison du niveau d'expression de HE4 dans l'échantillon au niveau d'expression de HE4 dans un échantillon préalablement obtenu auprès du sujet et éventuellement l'administration au sujet d'une quantité thérapeutiquement efficace d'un antagoniste de MUC16.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)